Nano Cap New Millennium Growth Fund L P Buys New Stake in Teladoc Health, Inc. $TDOC

Nano Cap New Millennium Growth Fund L P bought a new stake in Teladoc Health, Inc. (NYSE:TDOC) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 175,000 shares of the health services provider’s stock, valued at approximately $1,225,000.

Several other institutional investors have also recently added to or reduced their stakes in TDOC. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Teladoc Health by 2.8% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 193,714 shares of the health services provider’s stock valued at $1,542,000 after purchasing an additional 5,235 shares during the last quarter. NewEdge Advisors LLC increased its holdings in Teladoc Health by 1,278.7% in the 1st quarter. NewEdge Advisors LLC now owns 11,305 shares of the health services provider’s stock valued at $90,000 after purchasing an additional 10,485 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in Teladoc Health by 5.7% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 447,992 shares of the health services provider’s stock valued at $3,566,000 after purchasing an additional 24,124 shares during the last quarter. Acadian Asset Management LLC acquired a new stake in Teladoc Health in the 1st quarter valued at approximately $615,000. Finally, Envestnet Asset Management Inc. acquired a new stake in Teladoc Health in the 2nd quarter valued at approximately $89,000. Institutional investors and hedge funds own 76.82% of the company’s stock.

Insider Activity

In other news, CEO Charles Divita III sold 27,731 shares of Teladoc Health stock in a transaction on Wednesday, March 11th. The shares were sold at an average price of $5.49, for a total transaction of $152,243.19. Following the completion of the sale, the chief executive officer directly owned 364,784 shares of the company’s stock, valued at approximately $2,002,664.16. The trade was a 7.06% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.70% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently weighed in on TDOC. Canaccord Genuity Group dropped their target price on shares of Teladoc Health from $12.00 to $10.00 and set a “buy” rating for the company in a report on Thursday, February 26th. TD Cowen dropped their target price on shares of Teladoc Health from $8.00 to $6.00 and set a “hold” rating for the company in a report on Thursday, February 26th. Citigroup boosted their price target on shares of Teladoc Health from $6.00 to $7.00 and gave the stock a “neutral” rating in a research note on Tuesday, May 5th. Weiss Ratings restated a “sell (e+)” rating on shares of Teladoc Health in a research note on Friday, March 27th. Finally, Bank of America upgraded shares of Teladoc Health from a “neutral” rating to a “buy” rating and set a $7.00 price target for the company in a research note on Thursday, February 26th. Five research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $7.53.

Teladoc Health Price Performance

Teladoc Health stock opened at $6.55 on Friday. The stock has a market cap of $1.18 billion, a P/E ratio of -6.75 and a beta of 2.08. The company has a fifty day simple moving average of $5.83 and a 200-day simple moving average of $6.25. Teladoc Health, Inc. has a 12-month low of $4.40 and a 12-month high of $9.77. The company has a current ratio of 2.80, a quick ratio of 2.72 and a debt-to-equity ratio of 0.75.

Teladoc Health (NYSE:TDOC) last released its quarterly earnings data on Wednesday, April 29th. The health services provider reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.01). The firm had revenue of $613.85 million for the quarter, compared to analysts’ expectations of $611.04 million. Teladoc Health had a negative return on equity of 11.45% and a negative net margin of 6.81%.Teladoc Health’s revenue for the quarter was down 2.5% on a year-over-year basis. During the same period last year, the firm posted ($0.53) earnings per share. Teladoc Health has set its FY 2026 guidance at -1.050–0.750 EPS and its Q2 2026 guidance at -0.300–0.200 EPS. Equities analysts expect that Teladoc Health, Inc. will post -0.92 EPS for the current fiscal year.

Teladoc Health Profile

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.